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ABSTRACT
Autophagy is a lysosomal degradation and recycling process implicated in cancer 
progression and therapy resistance. We assessed the impact of basal autophagy in colon 
cancer (CC) in vitro and ex vivo. Functional autophagy was demonstrated in CC cell lines 
(LoVo; HT-29) showing a dose-dependent increase of the autophagy markers LC3B, 
p62 and autophagic vesciles upon increasing concentrations of the autophagy inhibitor 
chloroquine, which was demonstrated by immunoblotting, immunofluorescence and 
electron microscopy. Next, tissue microarrays with 292 primary resected CC, with cores 
from different tumor regions, and normal mucosa were analyzed by immunohistochemistry 
for LC3B and p62. CC tissue showed LC3B dot-like, p62 dot-like, cytoplasmic and nuclear 
staining in various levels without significant intratumoral heterogeneity. Tumoral 
LC3B and p62 expression was significantly higher than in normal tissue (p<0.001). No 
associations between staining patterns and pathological features (e.g. TNM categories; 
grading) were observed. Both low LC3B dot-like and low p62 dot-like-cytoplasmic staining 
were associated with worse overall survival (p=0.005 and p=0.002). The best prognostic 
discrimination, however, was seen for a combination of LC3B dot-like/p62 dot-like-
cytoplasmic staining: high expression of both markers, indicative of impaired activated 
autophagy, was associated with the best overall survival. In contrast, high LC3B dot-like/
low p62 dot-like-cytoplasmic expression, indicative of intact activated autophagy, was 
associated with the worst outcome (p<0.001 in univariate and HR=0.751; CI=0.607-
0.928; p=0.008 in multivariate analysis). These specific expression patterns of LC3B and 
p62 pointing to different states of autophagy associated with diverging clinical outcomes 
highlighte the potential significance of basal autophagy in CC biology.
INTRODUCTION
Colon Cancer (CC) is a malignancy with one of the 
highest incidences and is a major cause of cancer-related 
death worldwide [1, 2]. Individual CC treatment modality 
is based on tumor localization, tumor extent and biology, as 
well as additional patient specific factors. In the past several 
decades this strategy, compromising refined surgerical 
techniques in combination with adjuvant chemotherapy, 
highly improved the outcome for early and locally 
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advanced disease. However, CC morbidity and mortality 
is still generally high [3, 4]. Future medical oncology 
directives will focus on antitumor treatment that is targeting 
biological or molecular features of cancer. Autophagy is a 
cellular catabolic mechanism for the degradation of cellular 
components via the lysosomal pathway. Ultrastructurally 
and functionally autophagy is characterized by the formation 
of double-membraned vesicles called autophagosomes. 
Autophagy is initiated via the formation of a phagophore 
or nucleation membrane to which cytoplasmic content 
is targeted. The phagophore is elongated, resulting in a 
nascent autophagosome, which engulfs material marked 
for degradation and closes. Finally, mature autophagosomes 
fuses with lysosomes, resulting in autolysosomes, and 
content is degraded via catalytic enzymes. Sugars, fatty 
acids, amino acids and nucleosides are thus released back 
into the cytoplasm. Physiological functions of autophagy 
include maintainance of energy homeostasis, elimination 
of defective organelles and proteins, prevention of reactive 
oxygen species and removal of intracellular pathogens. 
Dysfunction of autophagy is associated with autoimmune, 
cardiac and neurodegenerative diseases, as well as cancer. 
In healthy cells, autophagy maintains normal metabolism, 
prevents inflammation, oxidative stress and DNA damage 
by removing damaged organelles and proteins. It is 
therefore theorized that in early stages of cancer, autophagy 
has tumor-suppressing properties. However, in late stages 
it is thought that autophagy allows survival, dormancy, 
growth and metastasis by providing an alternative energy 
source therefore exhibiting tumor-promoting properties [5, 
6]. Two widely used autophagy markers are microtubule-
associated protein 1 light chain 3 B (LC3B) and p62/
sequestosome 1 (SQSTM1). During autophagy the cytosolic 
LC3B-I form is converted into the lipidated LC3B-II form 
associated with autophagosomal membranes. p62 targets 
ubiquitinated substrats to autophagosomes via its interacts 
with LC3B. During autophagic flux both proteins are 
subject to degradation in autolysosomes [7, 8]. Several 
reports point to a role of autophagy in CC biology and 
treatment response. We aimed to investigate the impact of 
autophagy under basal conditions in vitro in CC cell lines 
and ex vivo in CC tumor tissue.
RESULTS
Investigation of intact functional basal 
autophagy of CC cells in vitro
The expression of the autophagy markers LC3B 
and p62 were assessed via immunofluorescence and 
immunoblotting after pharmacological autophagy 
inhibition with chloroquine, which prevents the fusion 
of autophagosomes and lysosomes by increasing 
lysosomal pH, in HT-29 and LoVo CC cell lines. 
Additionally, we visualized autophagic vacuoles via 
electron microscopy after chloroquine treatment. We 
found a dose-dependet increase of both autophagy 
markers LC3B and p62 with increasing concentrations 
of chloroquine as assessed by immunoblotting and 
immunofluorescence (Figure 1A and 1B). These 
results are indicative of functional basal autophagy in 
both cell lines. Electron microscopy results showed 
an increase in the formation of cytoplasmic vacuoles, 
often engulfing cellular components or organelles 
(Figure 1C). Although the typical double membraned 
characteristic could not be visualized, these structures 
can be interpreted as being autophagosomes as 
the decreased autophagosome degradation upon 
pharmacological autophagy inhibition can serve as 
plausible explanation for the presence of the abundant 
vesicles observed. Together, our data clearly indicate 
that both cell lines display functional basal autophagy.
Patho-clinical and prognostic implications of the 
expression of autophagy markers in CC tissue
We observed LC3B dot-like and p62 dot-like 
immunohistochemical staining was observed ranging 
from absent (score 0) to strong (score 3) in CC tissue 
and non-neoplastic colon mucosa. Additionally a 
range of p62 cytoplasmic as well as both negative and 
positive p62 nuclear immunohistochemical staining was 
reported (Figure 2). LC3B dot-like and p62 dot-like 
immunohistochemical staining showed a positive association 
(p<0.001). A positive association was also seen between p62 
dot-like and p62 cytoplasmic immunohistochemical staining 
(p<0.001). Tumor tissue from the tumor center and tumor 
periphery showed significantly higher amounts of LC3B 
dot-like, p62 dot-like, p62 cytoplasmic and p62 nuclear 
immunohistochemical staining compared to normal non-
neoplastic colon mucosa (p<0.001). There was no significant 
intratumoral heterogeneity with comparable staining 
patterns for all markers in the tumor center and the tumor 
periphery. No significant associations with staining patterns 
and pathoclinical features, such as pT category, presence 
of lymph node metastasis or distant metastasis, grading, 
as well as tumor location and MMR status were observed 
(Tables 1, 2 and 3). Survival analysis demonstrated that 
both low LC3B dot-like and low p62 dot-like-cytoplasmic 
stainings were associated with a worse overall survival, in 
univariate (p=0.005 for LC3B and p=0.002 for p62) and 
multivariate analysis (HR=0.599; CI=0.376-0.954; p=0.031 
for LC3B and HR=0.507; CI=0.285-0.902; p=0.021 for 
p62). In addition, the combination of LC3B dot-like and p62 
dot-like-cytoplasmic staining showed the best prognostic 
discrimination in univariate (p<0.001) and multivariate 
analysis (HR=0.751; CI=0.607-0.982; p=0.008). High 
expression of both markers, indicative of impaired activated 
autophagy, was associated with the best prognosis in contrast 
to high LC3B dot-like/low p62 dot-like-cytoplasmic, 
indicative of intact activated autophagy, staining with the 
worst prognosis (Table 4; Figure 3).
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In subgroup analyses, the prognostic impact of 
this classification was also seen for non-metastasized 
tumors (i.e. UICC/AJCC stages I-II; p=0.007), tumors 
with adjuvant treatment (p=0.041), left sided carcinomas 
(p=0.003) and MMR proficient carcinomas (p=0.002) in 
univariate analyses (Figure 4).
DISCUSSION
We investigated the impact of basal autophagy, 
focusing on two autophagy related proteins, in colon 
cancer. Immunoblotting and immunofluorescence results 
showed a dose-dependent increase of both autophagy 
marker proteins LC3B and p62 with increasing 
concentrations of autophagy inhibitor chloroquine. Since 
LC3B and p62 are incorporated into autophagosomes and 
subsequently degraded in autolysosmes, the accumulation 
of these proteins upon pharmacological autophagy 
inhibition is indicative of functional basal autophagy in the 
two CC cell lines tested [9]. Similarly, electron microscopy 
results indicated a dose-dependent increase in autophagic 
vesicles with increasing concentrations of chloroquine, 
supporting our immunoblotting and immunofluorescence 
data. Autophagic flux under nutrient starvation and 
steady state conditions with the use of pharamcological 
autophagy inhibition and LC3B detection in CC cell lines 
had been demonstrated before [10]; this is in line with our 
in vitro data, which shows intact autophagic machinery 
under steady state conditions in CC cell lines .
The current study also highlights the biological and 
prognostic impact of autophagy related markers LC3B 
and p62 ex vivo in CC tissue. In our cohort tumor tissue 
Figure 1: Assesment of functional basal autophagy in vitro. (A) Immunoblotting of LC3B and p62 upon pharmacological 
autophagy inhibition. A dose-dependent increase of LC3B and p62 was observed with increasing concentrations of chloroquine. (B) 
Immunofluorescence of LC3B and p62 upon pharmacological autophagy inhibition. I. In CC cell lines HT-29 and II. LoVo a dose-
dependent increase of LC3B and p62 was observed with increasing concentrations of chloroquine. (C) Electron microscopy of CC cell 
lines pharmacological autophagy inhibition. I-III. In CC cell line HT-29 a dose-dependent increase of cytoplasmic vesicles was observed 
with increasing concentrations of CQ.
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exhibited higher expression of both LC3B and p62, as 
detected via IHC, when compared to adjacent normal 
colon tissue. Interestingly no significant intratumoral 
heterogeneity, with respect to LC3B and p62 expression, 
was observed when comparing tumor center and periphery. 
When assessing single staining patterns, both low LC3B 
dot-like and low p62 dot-like-cytoplasmic stainings were 
associated with a worse outcome. To date several studies 
have been published which also report higher expression 
levels of LC3 and p62, together with other autophagy 
markers, in CC or colorectal cancer (CRC) tissue when 
compared to normal mucosa [11–13]. In contrast, others 
have also observed decreased expression of different 
autophagy associated proteins in CRC [14, 15]. As is 
the case when comparing autophagy marker expression 
levels in normal and cancer tissues, so too are the results 
regarding correlation to pathoclinical features divergent. 
Most papers report correlations between the expression 
of autophagy related proteins and the degree of tumor 
differentiation, but are inconstant with their findings 
[11–13, 16].
The body of literature also lacks consistancy 
regarding the prognostic impact and relevance of 
autophagy markers in CC and CRC. Some groups report 
that low expression levels of LC3 correlated with a worse 
prognosis and overall survival in their respective cohorts 
and studies, which is in line with our findings regarding 
single staining analysis [11, 14, 16]. Others found that LC3 
overexpression correlated with a worse overall survival, 
in part, however, only in specific molecular defined (i.e. 
KRAS-mutated) subpopulations [17].
The discrepencies found in the literature can be 
attributed to various confounding factors. It could be 
due to genetic differences in the cohorts stemming from 
different populations around the world. CC and CRC are 
very heterogeneous diseases and molecular characteristics 
such as KRAS, BRAF and microsatellite instability 
has not been used to further stratify cohorts. The fact 
Figure 2: LC3B and p62 immunohistochemical staining in CC tissue. (A) CC with low LC3B dot like staining. (B) CC with 
high LC3B dot like staining. (C) CC with both high p62 dot like and high p62 cytoplasmic staining. (D) CC with positive p62 nuclear 
staining (magnification 20X).
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Table 1: Correlation of LC3B dot-like immunohistochemical staining with patho-clinical features
Parameter N LC3B dot-like low LC3B dot-like high p-Value
pT category pT1 11 5 6 0.845
pT2 50 18 32
pT3 160 67 93
pT4 71 27 44
Lymph node metastasis Absent 180 67 113 0.359
Present 111 50 61
Distant metastasis Absent 252 102 150 0.695
Present 39 15 24
Grading G1-G2 195 83 112 0.169
G3-G4 97 34 63
Resection status R0 257 103 154 0.832
R1 35 14 21
Location Right 53 24 29 0.392
Left 239 93 146
MMR status Proficient 258 101 157 0.376
Deficient 34 16 18
Table 2: Correlation of p62 dot-like-cytoplasmic immunohistochemical staining with pathoclinical features
Parameter N p62 dot-like/cytoplasmic low p62 dot-like/cytoplasmic high p-Value
pT category pT1 11 1 10 0.209
pT2 50 5 45
pT3 160 19 141
pT4 71 15 56
Lymph node metastasis Absent 180 21 159 0.150
Present 111 19 92
Distant metastasis Absent 252 30 222 0.062
Present 39 10 29
Grading G1-G2 195 28 167 0.635
G3-G4 97 12 85
Resection status R0 257 31 226 0.004
R1 35 9 26
Location Right 53 9 44 0.442
Left 239 31 208
MMR status Proficient 258 32 226 0.076
Deficient 34 8 26
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that IHC staining and scoring protocols for the most 
commonly used autophagy markers, particularly LC3B, 
is not standardized, can also be an important confounding 
factor. Antibody specificity as well as interpretation of 
staining patterns can result in greatly varying results. Our 
group previously established and validated IHC staining 
and scoring protocol for LC3B (and p62) and found that 
only LC3B punctate staining patterns correlates with 
autophagy induction as opposed to diffuse cytoplasmic 
staining. The interobserver agreement was acceptable, 
especially after training, which made us comfortable 
to regard our evaluation results as reliable, despite the 
characteristic dot-like staining pattern that is not easy to 
score [18]. Few groups, however, distinguish between 
punctae and diffuse cytoplasmic staining patterns and 
thereby not discriminating between the LC3B-II isoform 
which is associated with autophagosomes and the LC3B-I 
isoform which is not. Standardizing IHC staining and 
scoring protocols for autophagy should be regarded as 
necessary steps towards using ATG proteins as biomarkers 
for research and potentially future routine diagonostic 
pratice for CC. However, using a snapshot of one protein 
of a highly dynamic process such as autophagy has its 
pitfalls, particularly when the markers used are themselves 
subject to autophagic degradation. Furthermore, single 
staining analysis gives limited insight into the underlying 
biological role of autophagy in any given disease setting. 
Therefore, in the present study we employed an analysis 
strategy, which involves formulating groups based on both 
LC3B and p62 staining in order to elucidate an autophagic 
index for each subpopulation. This approach was first 
applied on oral squamous cell carcinoma by others, where 
high cytoplasmic p62 expression accompanied with either 
a low or high LC3B expression, indicative of autophagy 
impairment under basal or activated autophagic activity, 
was associated with aggressive behaviour in advanced 
tumors [19]. In the current study, we report that the 
combination of LC3B dot-like/p62 dot-like-cytoplasmic 
staining showed the best prognostic discrimination. High 
LC3B dot-like/high p62 dot-like-cytoplasmic staining 
(indicative of impaired autophagy) was associated with 
the best prognosis, in contrast to high LC3B dot-like/
low p62 dot-like-cytoplasmic staining (indicative of 
activated autophagy) with the worst prognosis. This is in 
contrast to the findings of the OSCC study. However, our 
group subjected an esophageal adenocarcinoma cohort to 
similar analysis and found that the group with intact basal 
autophagy faired the worse [20]. The latter study suggests 
a similar underlying biology with respect to autophagic 
activity in upper and lower gastrointestinal cancers. Other 
authors created an autophagic score, compromising of 
the staining patterns of ATG5, Beclin1 and LC3B, and 
found that a low autophagic score correlated with a worse 
prognosis in CRC or demonstrated that a combination 
of Beclin1, LC3B and Bcl-xL (classically thought of 
as apoptosis marker) also showed better prognostic 
Table 3: Correlation of p62 nuclear immunohistochemical staining with pathoclinical features
Parameter N p62 nuclear low p62 nuclear high p-Value
pT category pT1 11 8 3 0.513
pT2 50 34 16
pT3 160 94 66
pT4 71 41 30
Lymph node metastasis Absent 180 119 61 0.069
Present 111 58 53
Distant metastasis Absent 252 152 100 0.417
Present 39 25 14
Grading G1-G2 195 119 76 0.497
G3-G4 97 58 39
Resection status R0 257 155 102 0.861
R1 35 22 13
Location Right 53 35 18 0.372
Left 239 142 97
MMR status Proficient 258 158 100 0.548
Deficient 34 19 15
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discrimination than analysis done on single staining [14, 
16]. This underscores the importance of the strategy taken 
in our current findings. However caution should be used 
when combining staining patterns of ATG genes, which 
are players at different stages of the autophagic process 
and it should be taken into account whether or not these 
proteins are subject to autophagic degradation and which 
staining patterns are associated with autophagy induction.
Autophagy has been described as a mechanism for 
tumors to develop resistance against chemotherapy or 
other kinds of cytotoxic treatment. Park et al. and Guo 
et al. reported on the association between the expression 
of autophagy markers and response to chemotherapy 
and targeted therapy against EGFR, respectively [21, 
22]. We analyzed the expression of LC3B and p62 in 
a subset of CC that had been treated with adjuvant 
therapy after surgery, which was the case for most of 
the lymph node metastases and in line with treatment 
recommendations for clinical practice. The prognostic 
impact of the expression of our markers and the 
combination, respectively, was comparable to the whole 
collection, and the direct comparison group of stage I-II 
tumors that usually do not receive adjuvant treatment. 
Therefore, we cannot draw significant conclusions 
regarding the role of tissue expression of LC3B and p62 
for chemotherapy reponse, although the number of cases 
in this particular subgroup was higher than reported 
from Park et al. [21].
Table 4: Multivariate analyses
A
Parameter HR 95% confidence interval p-Value
min max
pT category 1.397 0.98 1.99 0.064
Lymph node metastasis 1.942 1.199 3.147 0.007
Grading 1.046 0.634 1.724 0.86
Age 4.093 2.418 6.929 0.001
LC3B dot-like staining 0.599 0.376 0.954 0.031
B
Parameter HR 95% confidence interval p-value
min max
pT category 1.355 0.95 1.933 0.094
Lymph node metastasis 2.088 1.284 3.396 0.003
Grading 1.071 0.645 1.777 0.792
Age 4.084 2.409 6.921 0.001
p62 dot-like/cytoplasmic 0.507 0.285 0.902 0.021
C
Parameter HR 95% confidence interval p-value
min max
pT category 1.408 0.983 2.016 0.062
Lymph node metastasis 1.87 1.151 3.037 0.011
Grading 1.058 0.641 1.749 0.825
Age 4.024 2.374 6.82 0.001
LC3B dot-like/p62 dot-like-cytoplasmic 0.751 0.607 0.928 0.008
A) model including LC3B dot-like immunohistochemical staining; B) model including p62 dot-like-cytoplasmic 
immunohistochemical staining; C) model including the combination of LC3B dot-like/p62 dot-like-cytoplasmic 
immunohistochemical staining.
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Figure 3: Kaplan Meier survival analysis for LC3B and p62 immunohistochemical staining in CC tissue. (A) LC3B dot 
like staining (B) p62 dot like-cytoplasmic staining (C) p62 nuclear staining (D) combination of LC3B dot like/p62 dot like-cytoplasmic 
staining.
Figure 4: Kaplan Meier survival analysis for combined LC3B dot like/p62 dot like-cytoplasmic staining for subgroups. 
(A) Tumors with adjuvant treatment (B) non-metastasized tumors (i.e. UICC/AJCC stages I-II) (C) left sided carcinomas (D) MMR 
proficient carcinomas
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In summary, our study highlights the importance 
of autophagy in CC biology. Given that we observed 
no significant intratumoral heterogeneity with respect 
to expression levels of LC3B and p62, and tumors 
consistently showed higher expression levels when 
compared to normal mucosa, this strongly suggests that 
aberrant autophagic regulation and activity is an a priori 
state of the tumor, as opposed to a reactive process. Of 
note, we observed no difference in prognostic impact in 
the subgroup treated with adjuvant chemotherapy when 
compared to treatment naïve patients, which is in contrast 
to studies done in other tumor entities which report 
autophagy as a resistance mechanism activated upon 
cytotoxic treatment. However, given that the subgroups 
assigned with having activated autophagy exhibit 
the worse overall survival suggests that autophagy is 
exploited by the tumor entity as an oncogenic advantage. 
Elucidating the role of autophagy in CC therefore presents 
itself as a promising avenue to develop novel, targeted 
therapeutic strategies which would be feasible given 
the number of clinical trials involving pharmacological 
autophagy inhibitors currently ongoing for various tumor 
types [23–28].
MATERIALS AND METHODS
Cell lines, culture and treatment conditions
Human CC cell lines HT-29 and LoVo were 
obtained from ATCC LGC Standards GmbH, Switzerland. 
HT-29 cells were maintained and cultered in DMEM 
Medium (Sigma-Aldrich, D6046), supplemented with 
10% fetal bovine serum (Sigma-Aldrich, F7524), 1.25% 
L-Glutamine 1.25% and 1% penicillin/streptomycin. 
LoVo cells were cultered in F-12K Medium (Gibco Life 
Technologies, 21127022) supplemented with 10% fetal 
bovine serum (Sigma-Aldrich, F7524) and 1% penicillin/
streptomycin. Cells were treated with chloroquine 
(Sigma-Aldrich, C6628) at 25 µM and 50 µM for 24 
hours. Subsequently, cells were fixed or harvested for 
immunofluorescence or immunoblotting, respectively.
Immunofluorescence
Cells were washed in phosphate buffered saline 
(PBS), prefixed in 4% paraformaldehyde for 15s at room 
temperature (RT), fixed in ice-cold 100% methanol for 
10min at 20°C and washed PBS at RT. Primary antibodies, 
namely anti-LC3B antibody (Cell Signaling, Lausen, 
Switzerland, rabbit monoclonal, clone D11, #3686) and 
anti-p62 antibody (Sigma, Leiden, Netherlands, mouse 
monoclonal, clone 2C11, #WH0008878M1) were diluted 
1:100 and 1:200 in PBS/1% bovine serum albumin 
(BSA)/0.1% Tween, respectively. Slides were incubated 
with primary antibodies for 1h at RT. Slides was washed 
twice with PBS/0.1% Tween and once with PBS only. 
Secondary antibodies, namely FITC conjugated anti-
rabbit antibody (Jackson Immunoresearch, Suffolk 
United Kingdom, #111-096-045) and Cy3 conjugated 
anti-mouse antibody (Jackson Immunoresearch, Suffolk, 
United Kingdom, #115-166-003), were diluted 1:130 in 
PBS/1%BSA/0.1%Tween. Slides were incubated with 
secondary antibodies for 1h at RT. Images were taken 
on Olympus FluoView microscope at 63x objective 
magnification and adjusted for brightness using ImageJ 
Software (NIH, Bethesda, MD, United States of America, 
1.64r).
Immunoblotting
Cells were lysed in a buffer containing urea 8M, 
tritonX 0.5% and a protease inhibitor (Complete midi, 
Roche Diagnostics, Rotkreuz, Switzerland). Cells were 
sonicated and centrifuged at 13’000 rcf for 30min at 4°C. 
The supernatant was transferred to a fresh tube. Protein 
concentration was determined using Bradford protein assay 
(BioRad, Cressier, Switzerland). Protein totalling 30µg 
was denatured in sample buffer and β-mercaptoethanol at 
95°C for 5min. Samples were loaded on a 4-20% stain-
free pre-cast gel (BioRad, Cressier, Switzerland) using 
Mini-Protean® Tetra Vertical Electrophoresis Cell System 
(BioRad, Cressier, Switzerland) at 200V for 30min. 
Samples were transferred onto a polyvinylidene difluoride 
membranes using Trans-Blot® TurboTM Transfer System 
(BioRad, Cressier, Switzerland). Membranes were blocked 
with 5% BSA/TBS for LC3B and 5% milk/TBS for p62 
with shaking for 1h at RT. Primary antibodies, namely 
anti-LC3B antibody (LuBioScience, Luzern, Switzerland, 
rabbit polyclonal, #NB600-1384) and anti-p62 antibody 
(Sigma-Aldrich, Leiden, Netherlands, mouse monoclonal, 
#WH0008878M1), were diluted 1:1000 in 5% milk/
TBS/0.1%Tween. Membranes were incubated with 
primary antibodies with shaking overnight at 4°C. 
Secondary antibodies, namely DyLight®650 conjugated 
goat anti-rabbit antibody (LabForce, Switzerland) and 
DyLight®550 conjugated goat anti-mouse antibody 
(LabForce, Switzerland), were diluted 1:1000 in 5% 
milk/TBS. Membranes were incubated with secondary 
antibodies with shaking for 1h at RT. Total proteins and 
proteins of interest were acquired and visualized using 
ChemiDocTM MP System and Image Lab Software 
(BioRad, Cressier, Switzerland). Resulting images 
were adjusted for brightness in ImageJ Software (NIH, 
Bethesda, MD, United States of America, 1.64r).
Electron microscopy
HT-29 and LoVo grown and treated as decribed 
above on inserts (BD Falcon, Milan Dutscher Group, 
Nesselnbach/Niederwil, Switzerland, #353090) in six-
well-plates were processed for electron microscopy 
as follows: Each insert was fixed in a solution of 3% 
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Glutaraldehyde (25% EM Grade, Agar Scientific, Stansted, 
UK, AGR1010) in 0.1 M potassium phosphate buffer (total 
osmolarity 630 mOsm, pH 7.2). Thereafter the inserts 
were postfixed in a 1% solution of Osmium Tetroxide 
(Electron Microscopy Sciences, Hatfield, USA) in 0.1 M 
sodium cacodylate buffer (total osmolarity 356 mOsm, 
pH 7.2) and dehydrated in increasing concentrations of 
ethanol, 70%, 80%, 96% and 100%. The membranes of 
the inserts were cut out and embedded in Epon 812 (Sigma 
Aldrich, Wien, Austria, 45345-250ML-F). Ultrathin 
sections of 70 nm were cut in flat angle on a Reichert-Jung 
Ultracut E Microtome using a diamond knife (Diatome, 
Biel, Switzerland), put on 200 mesh hexagonal copper 
grids (Plano, Wetzlar, Germany) and double stained with 
1% Uranyl Acetate (Sigma Aldrich, Wien, Austria, 73943) 
and 3% Lead Citrate (Leica Microsystems, Heerbrugg, 
Switzerland, 16705530). Electron micrographs were taken 
on a Morgagni M268 Electron Microscope (FEI, Brno, 
Czech Republic).
Patient tissue samples
Formalin fixed and paraffin embedded (FFPE) tissue 
of colon adenocarcinoma resection specimens of 292 
patients was investigated. All patients had been treated by 
primary resection without neoadjuvant treatment between 
1993 and 2005 at Klinikum Rechts der Isar, Technische 
Universität München, München, Germany, as previously 
described elsewhere [29, 30]. Median age of the patients 
was 66 years (ranging from 25 to 91 years), male/female 
ratio was 160/132 and median survival was 74.5 months 
(ranging from 0 to 164 months). The tumor was located in 
right hemicolon in 53 cases (18.2%) and in left hemicolon 
in 239 cases (81.8%). The pT category (according to 
UICC 2009) was pT1 in 11 cases (3.8%), pT2 in 50 cases 
(17.1%), pT3 in 160 cases (54.8%) and pT4 in 71 cases 
(24.3%). Lymph node metastasis were absent in 180 
cases (61.9%) and present in 111 cases (38.1%). Distant 
metastasis at the time of surgery were absent in 254 cases 
(87.0%) and present in 38 cases (13.0%). Tumor grading 
was G1-G2 (well differentiated) in 195 cases (66.8%) 
and G3-G4 (poorly differentiated) in 97 cases (33.2%). 
Complete tumor resection was achieved in 257 cases 
(88.0%). Adjuvant treatment (chemotherapy) was given 
in 94 cases, of which the majority was stage III cancers. 
Consent for additional molecular analysis was given by 
the patient at the time of the surgery. The use of human 
tissue for additional molecular analysis was approved by 
the local ethics committee (2136/08).
Immunohistochemical staining, scoring and 
subclassification
Three punches (d=0.6mm) were taken from tumor 
center, tumor periphery and adjacent non-neoplastic colon 
mucosa to construct a next generation tissue microarray 
(ngTMA) with digital annotation of scanned slides 
and automatic transferal of the punches, as previously 
described [31]. After deparaffination, rehydration 
and antigen retrieval, immunohistochemical staining 
was performed on 4µm sections using an automated 
immunostainer Leica Bond RX (Leica Biosystems, 
Heerbrugg, Switzerland) as described before [18], as 
follows: LC3B (Novus Biologicals, Zug, Switzerland, 
rabbit polyclonal, #NB600-1384): 1:4’000, tris buffer, 
95°C, 30min; p62/SQSTM1 (LabForce mbl, Nunningen, 
Switzerland, rabbit polyclonal, #PM0045): 1:8’000, 
citrate buffer, 100°C, 30min. Visualization was performed 
using the Bond Polymer Refine Detection kit (Leica 
Biosystems, Muttenz, Switzerland, DS9800) according 
to the manufacturer’s instructions. Immunohistochemical 
stainings were scored across the respective cores of the 
different tumor regions, and finally for all cores of one 
tumor according to a previously established protocol 
which has also been applied in other studies [20, 32]. 
LC3B and p62 dot-like immunohistochemical staining was 
scored from 0 to 3 as follows: score 0 - no dots visible or 
barely dots visible in < 5% of the cells, score 1 - detectable 
dots in 5-25% of the cells, score 2 - detectable dots in 
25-75% of the cells, score 3 - dots visible in > 75% of 
the cells. p62 cytoplasmic immunohistochemical staining 
was scored from 0 to 3 as follows: score 0 - no or faint 
cytoplasmic staining visible, score 1 - weak cytoplasmic 
staining visible, score 2 - moderate cytoplasmic staining 
visible and score 3 - strong cytoplasmic staining visible. 
p62 nuclear immunohistochemical staining was scored 
from 0 to 1 as follows: score 0 - nuclear staining visible 
in < 10% of nuclei and score 1 - nuclear staining visible 
in > 10% of nuclei. Scoring was performed by two 
observers (MN and RL) on a Zeiss Axioscope microsope 
at 40x objective magnification. Discrepant results were 
re-evaluated at a double header microscope. Examples 
of LC3B and p62 immunohistochemical stainings are 
shown in Figure 2. For the purpose of correlation with 
pathoclinical features the immunhistochemical scores 
were catagorized as either low or high for each staining 
pattern according to the prognostic impact of the single 
scores, as described before [20, 32]. For LC3B dot 
like staining scores 0 and 1 were classified as low and 
scores 2 and 3 were classified as high. The low category 
of p62 dot like staining was assigned to score 0, while 
scores 1, 2 and 3 were assigned to the high category. p62 
cytoplasmic staining scores were similarly subdivided. 
p62 nuclear staining score 0 was classified as low and 
score 1 was classified as high. A combination score of p62 
dot-like-cytoplasmic staining was calculated by adding 
dot-like and cytoplasmic staining raw scores, with score 
0 and 1 being classified as low and scores 2 through 6 
being classified as high. In line with a previous study the 
dataset was also stratified into 4 subtypes: low LC3B 
dot-like/low p62 dot-like-cytoplasmic staining (LL), low 
LC3B dot-like/high p62 dot-like-cytoplasmic staining 
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(LH), high LC3B dot-like/low p62 dot-like-cytoplasmic 
staining (HL) and high LC3B dot-like/high p62 dot-like-
cytoplasmic staining (HH) [19]. Immunohistochemistry 
for mismatch repair (MMR) proteins was performed on 
the Leica Bond III autostainer as described [33]. Tumors 
were classified as MMR-proficient if MLH1, MSH2, 
PMS2 and MSH6 were expressed. MMR-deficiency was 
defined as absence of the expression of one or more of 
these markers.
Statistical analysis
The SPSS 23 software (SPSS Inc, Chicago, USA) 
was used for descriptive and comparative statistical 
analysis, for univariate and multivariable analysis, 
respectively. Associations between immuno-histochemical 
stainings and pathoclinical features were evaluated 
using cross tabs (Chi-square-test or Fisher’s exact test). 
Survival analysis was performed using log rank test 
and Cox regression analysis and was done for patients 
with complete tumor resection (R0) and without distant 
metastases (M0). The significance level was set at 0.05.
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